Your session is about to expire
← Back to Search
Virus Therapy
Cam2020 M2SR H3N2 influenza vaccine for Flu
Phase 1
Waitlist Available
Research Sponsored by FluGen Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 to day 29
Awards & highlights
Summary
This trial tests a new nasal spray flu vaccine (Cam2020 M2SR) in healthy adults aged 65 to 85. The nasal spray aims to boost immunity by mimicking the flu virus.
Eligible Conditions
- Flu
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1 to day 29
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 to day 29
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
SAEs through 28 days after experimental treatment
Solicited AEs during 7 days after experimental treatment
Unsolicited AEs during 28 days after experimental treatment
Trial Design
4Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: M2SR with IIV doseExperimental Treatment2 Interventions
Intranasal M2SR vaccine and intramuscular IIV dose
Group II: M2SR only doseExperimental Treatment2 Interventions
Intranasal M2SR vaccine and intramuscular placebo dose
Group III: IIV only doseActive Control2 Interventions
Intranasal placebo dose and intramuscular IIV dose
Group IV: Placebo only dosePlacebo Group2 Interventions
Intranasal placebo dose and intramuscular placebo dose
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cam2020 M2SR H3N2 influenza vaccine
2022
Completed Phase 1
~310
Fluzone HD IIV
2022
Completed Phase 1
~310
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
FluGen IncLead Sponsor
5 Previous Clinical Trials
460 Total Patients Enrolled
United States Department of DefenseFED
898 Previous Clinical Trials
332,420 Total Patients Enrolled
Pamuk BilselStudy DirectorFluGen Inc
2 Previous Clinical Trials
328 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger